Nycomed and Merck & Co. have agreed to co-promote the novel COPD therapy Daxas, which recently gained a positive recommendation in the EU. While this collaboration boosts Daxas' commercial prospects in several European countries, as well as Canada, the drug is limited by its restricted patient potential.
Edit my basket
© Datamonitor 2014. All rights reserved
Terms & Conditions